Herantis Pharma has made tangible progress towards raising funds to support its Phase II proof-of-concept study for lead asset HER-096 as a potential disease-modifier for Parkinson’s disease (PD). In early February, the company successfully completed a directed issue amounting to €4.2m (gross proce
